EGFR

News

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

GSK has paid Hutchmed $110m upfront for rights to a preclinical KRAS and EGFR-directed drug with potential in colorectal, pancreatic, and lung cancer.

Oncology

EGFR-mutant lung cancer: Cracking the drug resistance code

Targeted therapies have transformed the treatment landscape for non-small cell lung cancer (NSCLC) over the past decade.

News

Dizal breaks new ground for EGFR drugs in lung cancer

Dizal's Zegfrovy has taken the oral EGFR inhibitor class into new territory, with a phase 3 win as a frontline treatment for a form of lung cancer.

News

Survival data back Tagrisso's role in first-line lung cancer

Can survival data from the FLAURA2 trial of Tagrisso help AstraZeneca fend off a challenge from J&J's fast-growing rival in EGFR-mutated lung cancer?

News

Dizal set to bring lung cancer drug Zegfrovy to US

Dizal gets US approval for an oral therapy for EGFR exon 20-mutated NSCLC, offering some patients an alternative to J&J's intravenous Rybrevant.

News

ASCO 25: Merus bispecific scores again in HNSCC

For the second year running, data at ASCO on Merus' bispecific antibody petosemtamab in head and neck cancer has drawn the eye.

Hutchmed rises on $1.3bn KRAS licensing deal with GSK

EGFR-mutant lung cancer: Cracking the drug resistance code

Dizal breaks new ground for EGFR drugs in lung cancer

Survival data back Tagrisso's role in first-line lung cancer

Dizal set to bring lung cancer drug Zegfrovy to US

ASCO 25: Merus bispecific scores again in HNSCC

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

EGFR

Editor's Picks